Cdpath will be available for all U.S. physicians and patients can have blood drawn for the test at one of the 2,500 partner locations nationwide.
Cdpath uses patient-specific genetic markers identified in the blood sample, along with a patient’s Chrohn’s disease characteristics, to predict whether a patient has a low, medium or high risk for developing serious Crohn’s disease complications.
Physicians can use the report, along with a clinical assessment, to discuss patient options moving forward.
“Having a better understanding of their underlying disease can help patients take a more proactive role in their Crohn’s disease management,” Corey Siegel, MD, section chief of gastroenterology and hepatology and co-director of the IBD center at the Dartmouth Hitchcock Medical Center, said in the release. “For physicians, shared decision-making is a key component to a patient-centric management approach. CDPATH will allow healthcare providers to evaluate the potential variability and complexity of Crohn’s disease for each individual patient, and support a more collaborative approach to managing their patient’s CD.”
